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 A novel chalcone was characterized using NMR, IR, UV-Vis, XRD 
and HSA analysis. 
 The chelating studies with some metal chloride were performed using 
UV-vis.  
 The chalcone shows biometal chelating ability and moderate 
antioxidant activity. 
 The bio-studies of chalcone revealed 33-fold better inhibition than 
donepezil. 
  A molecular modelling study of the chalcone shown dual binding 
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Abstract: 
The design of an acetylcholinesterase inhibitor with multifunctional properties became 
the perspective for the development of an effective drug against Alzheimer’s disease. 
Towards this target, 1-{4-hydroxy-3-[(piperidin-1-yl)methyl]phenyl}ethan-1-one 
(chalcone 3) was prepared and studied as an acetylcholinesterase inhibitor. The novel 
chalcone 3 was synthesised via Claisen-Schmidt condensation reaction with 84% yield 
and characterized using 1D and 2D NMR spectroscopy.  The in vitro bioactivity studies 
of chalcone 3 demonstrated excellent inhibitory activity against AChE (IC50 1.0 nM) 
showing 33-fold better inhibition than donepezil, biometal chelating ability and moderate 
antioxidant activity. Chalcone 3 with these fascinating multifunctional proprieties can be 
a good candidate for the development of AD treatments. A molecular modelling 
investigation revealed that chalcone 3 showed dual binding inhibition of AChE enzyme. 
XRD shows short intra- and inter-molecular interactions with two chalcone 3 molecules 
per cell. Interesting Hirshfeld Surface Analysis (HSA) was conducted showing explicit 
agreement with the XRD analysis. 
Keywords: 
Acetylcholinesterase (AChE); metal chelation; NMR titration, molecular docking, XRD, 
Hirshfeld Surface Analysis    
1. Introduction 
         
Chalcones are α,β unsaturated carbonyl compounds with a 1,3-diphenyl-2-propene-1-one 
framework [1]. They are open-chain flavonoids with two aromatic rings linked by an 
aliphatic three-carbon chain. Chalcones are an essential component in natural products 
and play a key role in synthetic manipulations [2].  
Although naphthalene has toxic effects [3], some of its derivatives are bestowed with 
medicinal value [4], and several of them have been characterised as antioxidants [5]. 
Considering both the cytotoxic and antioxidant properties of naphthalene derivatives, 
organic and medicinal chemists are trying to design drugs that have maximum therapeutic 
index and minimum toxicity so that they can be used as therapeutics [6]. Some 
investigations have been conducted to synthesise chalcones using naphthaldehyde [7,8].  
Alzheimer's disease (AD) has received considerable attention because it is the most 
common cause of dementia. According to the World Health Organization, it accounts for 
60–70 per cent of dementia cases worldwide [9]. Cholinesterase inhibitors (ChEIs) are 
the only class of agents that have so far consistently proved effective in treating the 
cognitive and functional symptoms of AD [10]. Medications approved by the U.S. Food 
and Drug Administration (FDA) for AD belong to a category of acetylcholinesterase 
inhibitors, but most of them were found to have side effects [11]. 
A trend has developed recently to use naturally occurring and synthetic derivatives of 
chalcones as cholinesterase inhibitors due to their slight side effects [12]. Recent studies 
on AD have confirmed that  a Mannich base and chalcone, when incorporated into a 
single pharmacophore, displayed moderate inhibitory effect for AChE with excellent 
multifunctional properties [13,14]. 
Metal chelators and reactive oxygen species (ROS) scavengers have demonstrated 
potential therapeutic capacity in treating  AD due to the increased level of metal ions in 
the plaque [15]. Iron, copper and zinc are essential elements for properly maintaining 
neurological functions in the brain. However, their abnormal levels have been observed 
in several subcortical regions of the AD brain tissues [16]. N-terminal amino acid 
residues contain metal binding sites that are capable of coordinating transition metal ions 
with high affinity. These metal ions significantly affect the aggregation behaviour of 
Amyloid β-protein (Aβ) [17,18]. Metal-binding at these sites can accelerate Aβ 
         
aggregation and generate more amorphous aggregates, including neuro-toxic oligomers 
[19]. A relationship between increased aluminium exposure and AD has been found in 
some studies [20]. It has been also reported that aluminium can play a role in the 
aetiology of AD because of its ability to increase oxidative stress caused by iron and 
other metals [21]. 
This study is a follow-up of our comprehensive research on designing and synthesising 
chalcone derivatives as acetylcholinesterase inhibitors using Mannich bases. Hence, the 
spectroscopic data for 1-{4-hydroxy-3-[(piperidin-1-yl)methyl]phenyl}ethan-1-one 
(chalcone 3) have been invesitgated to help understand the structural and geometrical 
features of the novel chalcone in the crystal lattice. To investigate possible binding 
interactions with the target enzyme, a molecular modelling study was performed using 
the experimental crystal structure data of the title compound 3. Hirshfeld Surface 
Analysis (HSA) clarifies details of intermolecular interactions derived from the X-ray 
analysis. 
2. Experimental  
2.1 Synthesis of chalcone  
2-Benzyloxy-1-naphthaldehyde (1) was obtained via an alkylation reaction of 
commercially available 2-hydroxy-1-naphthaldehyde in a typical, published procedure 
[22]. 1-{4-Hydroxy-3-[(piperidin-1-yl)methyl]phenyl}ethan-1-one (2) was synthesised 
by means of the Mannich reaction of 4-hydroxyacetophenone with piperidine and 
formaldehyde according to the method reported earlier [23]. The starting materials 
underwent a Claisen-Schmidt condensation reaction to produce chalcone 3 as yellow 
crystals in an excellent yield (84%) with melting point of 137-140 °C (Scheme 1) [24–
26].  
         
 
Scheme 1. Synthetic route to the title chalcone 3. 
2.2 Crystal structure of chalcone 3 and Hirshfeld Surface Analysis 
 
Recrystallisation of chalcone 3 using cold ethanol provided a suitable crystal for X-ray 
analysis. Crystals are pale yellow plates and, from a sample under oil, one, ca 0.23 x 0.28 
x 0.43 mm, was mounted on a glass fibre and fixed in the cold nitrogen stream on an 
Oxford Diffraction Xcalibur-3/Sapphire3-CCD diffractometer, equipped with Mo-Kα 
radiation and graphite monochromator. Intensity data were measured by thin-slice φ-
scans. Total no. of reflections recorded, to θmax = 27.5, was 23161 of which 6372 were 
unique (Rint = 0.037); 4826 were observed with I > 2σI.  
Data were processed using CrysAlis PRO 1.171.39.46 [27] for cell refinement and data 
reduction. Program used to solve structure: SHELXT [28a]; program used to refine 
structure: SHELXL2014/7 [28b]; molecular graphics: ORTEP [29]; software used to 
prepare material for publication: SHELXL2014/7 [28b] and WinGX [29].  
Crystal data: C32H31NO3, C2H6O, M = 523.64. Triclinic, space group P-1 (no. 2), a = 
10.6946(5), b = 11.7088(5), c = 13.5975(5) Å, α = 96.356(4), β = 107.209(4), γ = 
116.643(5) , V = 1393.45(12) Å
3
. Z = 2, Dc = 1.248 g cm
-3
, F(000) = 560, T = 140(1) K, 
μ(Mo-Kα) = 0.81 cm
-1
, λ(Mo-Kα) = 0.71073 Å. 
Hirshfeld surface analysis and the related 2D-fingerprint plots were calculated using 
Crystal Explorer, which reads a structure input file in CIF format [30]. 
 
         
2.3 Metal-chelating studies 
 
The metal chelating studies were performed on chalcone 3 using the Shimadzu 
UV-1601 spectrophotometer and Bruker 400MHz NMR spectrometer. The UV−Vis 
absorption spectra of chalcone 3 in methanol (50 μM) alone and in the presence of CuCl2, 
ZnCl2, AlCl3, and FeCl2 (50 μM in methanol) were recorded with wavelength ranging 
from 200 to 600 nm in situ at room temperature. The molar ratio method was used to 
determine the stoichiometry of the complex 3-Fe
2+
 by titrating the methanol solution of 
chalcone 3 in a fixed concentration (60 μM) with increasing concentration of FeCl2 (6-
100 μM). The UV−Vis spectra were recorded at 307 nm and treated by numerical 
subtraction of FeCl2 and 3 at corresponding concentrations, plotted versus the mole 
fraction of 3. For NMR titrations, chalcone 3 (9 mg, 0.019 mmol) was dissolved in 
CD3OD (1 mL) for 
1
HNMR analysis using a micro NMR tube and the spectrum was 
recorded before titration. Then FeCl2 (19 μM) solution (in D2O) was titrated 
progressively using a micropipette within the NMR tube to monitor the 
1
HNMR in situ. 
Spectra 2-6 were recorded upon the addition of the increasing equivalents of FeCl2. 
2.4 In vitro bioactivity studies of chalcone 3 
2.4.1 Antionxidant activity analysis 
 
The antioxidant evaluation was performed against 2,2-diphenyl-1-picrylhydrazyl (DPPH) 
free radical based on the method described by Hamad et al. [31]. A series of dilutions 
ranging from 10 μg/ml to 13 mg/ml was prepared in methanol. An aliquot of 40 μL of 
chalcone 3 from each serial dilution was mixed with 160 μL of freshly prepared 
methanolic solution of 100 μM DPPH radical and kept in the dark. After 30 min of 
incubation, the decrease in absorbance at 517 nm was determined. The absorbance of the 
DPPH radical without antioxidant (blank) and the reference compound ascorbic acid 
were also measured. All the determinations were performed in three replicates and 
averaged. The percentage inhibition of the DPPH radical was calculated according to the 
formula: 
Percentage Inhibition (%) = 
                 
      
  100 
         
where Ablank = absorbance of the blank solution (containing DPPH solution without 
sample) and Asample = absorbance of a sample solution. The concentration affording 50% 
inhibition (IC50) values were calculated using GraphPad Prism for Windows (version 
8.3.0) software. 
2.4.2 Inhibition of AChE enzyme activity 
 
The acetylcholinesterase inhibitory activity of chalcone 3 was determined by Ellman's 
microplate assay described by Koay et al.(2014) [32]. 140 µl of 0.1 M sodium phosphate 
buffer (pH 8) was added first followed by 20 µl of the test sample (in 10% methanol) and 
20 µl of 0.09 unit/ml AChE from Electrophorus electricus (Electric eel). After pre-
incubation at room temperature, 10 µl of 10 mM 5,5′-dithiobis (2-nitrobenzoic acid) 
DTNB was added into each well followed by 10 µl of 14 mM acetylthiocholine iodide as 
substrate. The absorbance of the coloured product was measured using a microplate 
reader at 412 nm following 30 minutes incubation. Donepezil hydrochloride (Sigma-
Aldrich) was used as a positive control. Percentage inhibition was calculated using the 
following formula for eight different concentrations: 
Percentage Inhibition (%) = 
                                              
                     
 100 
Three replicates of the sample were used for statistical analysis with values reported as 
mean ± S.D. Standard curves were generated and the 50% inhibitory concentration (IC50) 
values were calculated using GraphPad Prism.  
2.5 Molecular docking  
 
A docking study was carried out using AUTODOCK 4.2 [33]. The X-ray crystal structure 
of the acetylcholinesterase complexed with donepezil (PDB code: 1EVE) was obtained 
from the Protein Data Bank (https://www.rcsb.org/structure/1eve). All ligands and water 
molecules were removed from the retrieved protein using Discovery Studio Visualizer 
v17.2.0.16349 [34]. The experimental crystal structure of chalcone 3 was converted to 
PDB file and used for docking after the removal of the co-solvent (ethanol). The 
         
chalcone-protein interactions were analysed and visualised in two-dimensional (2D) 
diagrams using Discovery Studio Visualizer. 
3. Results and discussion 




H NMR spectrum of chalcone 3 showed an AB spin system at ẟH 7.97 and 8.36 (d, J 
= 15.4 Hz) attributed to H-β and H-α, respectively as presented in Fig. 1. These two 
doublets are characteristic of the trans-olefinic protons of chalcone. The remaining 
aromatic protons were assigned based on the COSY spectrum (Fig. 2). The 
13
C NMR and 
DEPT spectra displayed twenty-eight carbon signals, including five methylenes, fourteen 
methines, eight quaternaries and one carbonyl carbon (Fig. S1). The HMQC spectrum 
displayed direct correlations between protons and carbons in the compound, thus 
confirmed the assignment of the protonated carbon peaks at δC 22.78 (C-9ʹ/11), 71.20 (C-
1ʺ), 128.67 (C-5ʺ), 128.74 (C-4ʺ/6ʺ), 129.10 (C-3ʺ/7ʺ) (Fig. S2). HMBC spectrum was 
reported to confirm the assignment of protons and carbons. The spectrum Fig. S3 
exhibited the presence of correlation between A2B2 aromatic protons at δH 7.57-7.63 (H-
3", H-7") with C-4",6 " (δC 128.74), while protons at δH 7.38-7.47 (H-4ʺ, H-6ʺ) were 





HMQC and HMBC spectral data of chalcone 3 are listed in Table 1. 











H COSY spectrum of chalcone 3 
 



































Position δH δC COSY HMBC 
 

























crystallographic data and final agreement parameters are collected in Table 2. Selected 
bond angles and distances are collected in Table 3. The molecular structure of 3 with 
atomic numbering is shown in Fig. 3(a) and Table 4. With one co-crystallized solvent 
molecule, X-ray single-crystal structural analysis revealed that compound 3 is triclinic, 
space group P-1, with two chalcone 3 molecule per cell. The bonds around the piperidine 
N atom, C30–N31, N31–C36, N31–C32 are 1.4736 (15) 1.4705 (16) and 1.4740 (16) Å 
respectively which are slightly shorter than the normal C–N bond, 1.50  
 
Table 2 Crystal data and structure refinement details for 2-Benzyloxynaphthylchalcone 3 
1 - 132.93  
 
2 - 156.84  
 
3 8.06 (d, J = 9.2 Hz) 132.54 H-4 C-2, C-1 
4 7.67 (d, J = 9.2 Hz) 115.15 H-3 C-2, C-9, C-10 
5 8.20 (d, J = 8.8 Hz) 123.19 H-6 C-7, C-9, C-10 
6 7.57-7.63 (m) 128.36 H-5, H-7 C-8 
7 7.38-7.47 (m) 124.53 H-6, H-8 C-5 
8 7.94 (d, J = 8.8 Hz) 129.30 H-7 C-1, C-6, C-10 
9 - 129.18  
 
10 - 116.77  
 
α 7.97 (d, J = 15.8 Hz) 126.76 H- β C=O, C-1 
β 8.36 (d, J = 15.8 Hz) 136.06 H- α C=O, C-2, C-1, C-α 
1ʹ - 129.74  
 
2ʹ 8.16 (d, J = 2.0 Hz) 134.91  C-4ʹ, C-6ʹ, C-7
 ́
3ʹ - 117.17  
 
4ʹ - 161.76  
 
5ʹ 7.02 (d, J = 8.8 Hz) 116.06 H-6ʹ C-1ʹ, C-3ʹ, C4ʹ 





7ʹ 4.21 (s) 54.02  C-2ʹ, C-3ʹ, C4ʹ, C-8ʹ 
8ʹ, 12 2.97 (br s) 52.32   
9ʹ, 11 1.75 (br s) 22.78   
10ʹ 1.50 (br s) 21.66   
1ʺ
 
5.43 (s) 71.20 











7.57-7.63 (m) 129.10  C-4ʺ,  C-6ʺ 
4ʺ, 6ʺ 7.38-7.47 (m) 128.74  C-3ʺ, C- 7ʺ, C-5ʺ 
5ʺ  7.38-7.47 (m) 128.67  
 
C=O - 187.88   
Experimental data measured at 400 MHz in DMSO 
         
C32H31NO3C2H6O Mr = 523.64 
F(000)= 560   
Triclinic, P-1 (no. 2)  Dx = 1.248 Mg m
−3
 
a = 10.6946 (5) Å Mo Kα radiation, λ = 0.71073 Å 
b = 11.7088 (5) Å 
Cell parameters from 7929 reflections, 
θ = 3.3–32.4 
c = 13.5975 (5) Å θ = 3.3–32.4° 
α = 96.356 (3)° µ = 0.08 mm−1 
β = 107.209 (4)° T = 140 K 
γ = 116.643 (5)° Wedge, pale yellow 
V = 1393.45 (12) Å3 0.43 × 0.28 × 0.23 mm 
Z = 2 
 
Oxford Diffraction Xcalibur 3/Sapphire3 CCD  
diffractometer 
6372 independent reflections 
Radiation source: Enhance (Mo) X-ray Source 4826 reflections with I > 2σ(I) ‘observed’ 
Graphite monochromator Rint = 0.037 
Detector resolution: 16.0050 pixels mm-1 θmax = 27.5°, θmin = 3.7° 
R1(‘observed’ data) = 0.045 
H atoms treated by a mixture of independent 
and constrained refinement  
wR2(all data) = 0.125 













S = 1.09 (Δ/σ)max = 0.001 
6372 reflections Δρmax = 0.41 e Å
−3
 




Table 3 Selected geometric parameters (Å, °)  of compound 3 
C2—O2 1.3627 (15) C30—N31 1.4736 (15) 
O2—C20 1.4366 (17) N31—C36 1.4705 (16) 
C13—O13 1.2293 (16) N31—C32 1.4740 (16) 
C17—O17 1.3574 (14) O41—C42 1.429 (2) 
         
O2—C2—C1 116.23 (11) C30—N31—C32 111.00 (10) 
O2—C2—C3 121.49 (12) C2—O2—C20 120.63 (10) 
O13—C13—C12 121.20 (11) N31—C36—C35 110.18 (11) 
O13—C13—C14 120.66 (11) O41—C42—C43 112.99 (17) 
O17—C17—C18 117.94 (12) O17—C17—C16 121.79 (11) 
O2—C20—C21 10105.48 (11)   
 
 
Table 4 Hydrogen-bond geometry (Å, °) of compound 3 
D—H···A D—H H···A D···A D—H···A 
C12—H12···O2 0.93 2.13 2.7297 (16) 121 
C20—H20B···O41i 0.97 2.59 3.4797 (18) 153 
O17—H17O···N31 0.93 (2) 1.73 (2) 2.6165 (16) 157.5 (16) 
O41—H41O···O13 0.92 (3) 1.90 (3) 2.7980 (17) 168 (2) 
Symmetry code: (i) x−1, y−1, z. 
 
Å [35]. The molecule exhibits short intra- and inter-molecular interactions. An 
intramolecular hydrogen bond links the hydroxyl group of O(17) with the piperidine 
N(31) atom, and the solvent ethanol molecule forms a good hydrogen bond with the 
carbonyl O(13) atom, Table 4 and Fig. 3(a).  The molecule comprises three planar 
aromatic ring groups and a chair-shaped piperidine ring.  The hinge atoms between the 
planar groups are C(20) and C(12), with the piperidine group hinged at C(30). The 
naphthyl group lies parallel (at a distance of 3.476 Å), and related about a centre of 
symmetry, to a neighbouring group with extensive π…π interactions.  The chain of C(11, 
12, 13, 14, 19, 18, 17) and O(17) overlies a symmetry-related chain, also with close π…π 
interactions and at a distance of 3.375 Å. Fig. 4(b).  Fig. 3(b) illustrates the molecular 
interactions in compound 3 by showing red, white and blue colors; the presence of red 
areas around some atoms indicates strong internal and external interactions.  
         
‘Fingerprint plots’ from the Hirshfeld surface analysis, Fig, 5, show that H...H contacts 














O contacts account for 10.4% of interactions (di + de 
= 2.4 Å), (Fig. 5). Interestingly, C…C interactions for 3 account for 5.2% of contacts, 
indicating good π
…
π stacking.  














Fig. 3 (a) An ORTEP diagram of 3 showing the atom-labelling scheme. Thermal ellipsoids are shown at 50% probability, (b) Hirshfeld surfaces 
views of the molecule 3 mapped over dnorm with enabled surface transparency. The red and blue regions represent negative and positive electrostatic 









(a) (b) (c) 






Fig. 4 (a) A projected view of the molecular packing of 3, (b) A pair of overlaying molecules of 3 
showing the distance between calculated centroids. The distance between the overlapping rings is 
ca 3.42 Å. This view was drawn using Mercury [36]. Hydrogen atoms are omitted for clarity and 



















N interactions. The outline of the full fingerprint is shown in gray. di is the closest internal 
distance from a given point on the Hirshfeld surface and de is the closest external distance. 
 
3.3 Metal-chelating properties  
 
Considering the implications of metals in AD pathogenesis, the chelating ability of 








, was evaluated using 
ultraviolet-visible (UV–Vis) spectrometry. The metal complexation capacity of chalcone 
3 was investigated in situ using UV−Vis absorption. Interestingly, the maximum 
absorption at 338 nm was shifted to 307 nm after the addition of FeCl2, which indicated 
the possible formation of a 3-Fe
2+
 complex. The difference in the UV−Vis absorption 
peaks (31 nm) between the free ligand and the Fe(II) complex is probably due to changes 
in the molecular/electronic conformation effect caused by complexation, Figs. 6 and 8 
         
[37]. The addition of AlCl3 and CuCl2 exhibited marginal blue shift of the maximum absorption 
from 338 to 329 nm. However, no significant change was observed with the addition of ZnCl2.  
To consider the stoichiometry of the resulting complex 3-Fe
2+ 
using the molar ratio 
method, chalcone 3 in a fixed concentration (60 μM) was mixed with increasing 
concentrations of FeCl2 (6-100 μM). The absorbance of the resulting complex of FeCl2 
and 3 was recorded using a UV-Vis spectrometer at 307 nm. As displayed in Fig 7, the 
absorbance increased linearly at first, before plateauing when the mole fraction of Fe
2+
 to 






Fig. 6 UV−Vis spectra of chalcone 3 in methanol (60 μM) alone and titrated with CuCl2, FeCl2, 



















3-Al 3 3-Cu 3-Zn 3-Fe
         
 
Fig. 7 The stoichiometry of complex 3-Fe
2+
 via the molar ratio method  
 
To highlight the metal chelating sites a deuterium methanolic solution of chalcone 3 (19 
μM) was titrated in situ with increasing equivalents of FeCl2 solution (19 μM). The 
progress of the complexation was monitored using
1
H NMR spectroscopy as presented in 
Fig. 8. The spectra indicated that the signals of the piperidine protons have been split to 
five different signals due to the coordination of Fe
+2
 with the nitrogen atom; compared to 
the crystal structure 
1
H NMR spectrum, which showed three broad singlet signals 
attributed to three sets of equivalent CH2 groups of the piperidine moiety, this suggests 
that the chalcone conformation was changed upon complexation. Moreover, the 
methylene protons (Hb) have been shifted upfield upon complexation. Similarly, the 
benzyloxy protons have been shifted upfield which indicated coordination via its oxygen. 
The structure involved the ferrous(II) ion being coordinated through the lone pair 
electrons of both nitrogen and oxygen atoms, correlated to Mannich base and benzyloxy 
moieties respectively, and forming, probably, an octahedral structure, the common 
geometric structure for Fe(II) in the presence of water/methanol molecules in solution 
[38]. Because it was not possible to obtain a suitable single crystal for X-ray study, the 


























 Mole fraction of Fe (II) to compound 3 
         
be a suitable tool to provide enough information for us to describe the way of bonding of 
the ligands. Therefore, a detailed elucidation of IR spectra of the chalcone ligand and the 
effect of binding of iron(II) on the vibration frequencies of the chalcone ligand are 
highlighted to conclude that the coordination mode involves chelation. The IR spectrum 
of the precipitated complex (3-Fe
2+
) confirmed the coordination sites due to the presence 
of a broad absorption band at 3432 cm
-1 
for the hydroxyl group and a very weak 
stretching vibration at 2946 cm
-1
 for the aliphatic C-H. Additionally, it showed an 
absorption frequency at 1604 cm
-1
 implying the presence of a conjugated carbonyl group 






H-NMR titration of compound 3 with FeCl2 in CD3OD. Spectra 2-6 recorded upon the 
addition of increasing eq. of FeCl2   
 
3.4 In vitro bioactivity evaluations of chalcone 3 
The novel chalcone 3 exhibited potent inhibitory activity against Electric eel AChE with 
IC50 1.0 nM showing better inhibition than donepezil (IC50. 33.4 nM). Furthermore, it 
showed comparable scavenging inhibitory activity towards DPPH comparable to that of 








         
 
Table 5 Cholinesterase and DPPH activities of chalcone 3  
Compound AChE IC50 (nM) ± SD DPPH Radical IC50 µg/ml 
3 1.0 0.003 55.52  1.1 
Donepezil 33.4  0.002 - 
AA - 17.96  0.4 
IC
50 
±SD: Inhibitor concentration (mean  ± S.D. of three experiments) needed for 50% inhibition 
of the enzyme; AA (Ascorbic acid)
 
 
3.5 Binding prediction of chalcone 3 using molecular docking 
 
Docking analysis was carried out using the elucidated crystal structure data of chalcone 3 
to screen its binding affinity on the Torpedo california acetylcholinesterase (TcAChE) 
(PDB 1EVE). Chalcone 3 displayed tight binding against the TcAChE enzyme with low 
binding energy -13.29 kcal/mol in comparison to donepezil (-10.52 kcal/mol). 
Superimposition of 3 (yellow stick) and donepezil (grey stick) as shown in Fig. 9 
demonstrates the benzylic moiety in ring B is directed towards the peripheral anionic site 
(PAS), while the three planar aromatic rings of chalcone 3 turned the piperidine ring 
towards the catalytic anionic site (CAS) similar to donepezil.  We note that the molecular 
structure of 3 has changed drastically after binding with the protein when compared to the 
free molecule. Comparison of the interactions of chalcone 3 and donepezil within the 
active site of AChE revealed that there is considerable flexibility of the chalcone 3 
molecule that facilitates the interaction between piperidine and the binding site for the 
quaternary nitrogen of AChE, TRP84 via π-alkyl interactions with distances of 5.30 and 
5.01 Å in line with donepezil (Fig. 9). TRP84 was considered the principal component of 
the anionic site [39]. However, two hydrogen bonds were found between the hydroxyl 
group at ring A of 3 and residues GLY118, and GLU199 at the oxyanion site with 
distances 2.87 and 2.18 Å respectively Fig. 10(a). Moreover, a hydrogen bond was found 
between the hydroxyl group of TYR121 at the PAS site and benzyloxy group at ring B 
with distance 2.65 Å. Furthermore, hydrophobic interaction with the PAS was observed 
between the benzyl moiety of chalcone 3 and the residue ASP70. This residue is a vital 
component of the PAS site as several studies have reported its role as a trap for charged 
         
substrate, thus contributing to catalytic efficiency. Similar transient binding also occurs 
with cationic organophosphates [40,41]. It is also worth noting that at the bottom of the 
gorge, a CH···π T-shaped hydrophobic interaction was observed between ring A of 
chalcone 3 and the phenyl moiety of HIS440, a residue of the catalytic triad in the active 
site of AChE [42]. These interactions were not observed in donepezil and might 
contribute to the affinity to the enzyme hence improving the inhibition effect of chalcone 
3. Overlay of the crystallographic structure (magenta) and the docked (green) 
conformations of chalcone 3 suggests that the presence of methylene groups might be 
responsible for the chalcone structural flexibility as presented in Fig. 11.  
Therefore, we propose that the novel chalcone 3 shows potent in vitro inhibitory activity 
towards AChE when compared with donepezil.  
 
 
Fig. 9 Docking model of TcAChE-3 complex showing superimposition of the ligand 3 (yellow 
stick) with donepezil (grey stick) in the active site of 1EVE (a). The interacting mode of chalcone 





         
  





         
 
Fig. 11 Overlay of crystallographic (magenta) and docked (green) conformations of chalcone 3  
 
4. Conclusion  
Interesting HS analysis was accomplished for the 2-benzyloxynaphthalene 
aminoalkylated chalcone 3. The in vitro analysis of chalcone 3 showed potent inhibitory 
activity against AChE with moderate scavenging ability toward DPPH. Moreover, the 
chalcone 3 was able to coordinate with the biometal FeCl2 in a stoichiometry ratio 1:1 to 
form the complex 3-Fe
2+
 based on the UV−Vis and the NMR analysis. Molecular 
docking analysis was used to further explore the binding mode of 3 with AChE and to 
investigate the efficacy of introducing Mannich base and benzyl moieties into a 
naphthalene-based chalcone. The molecular modelling proves the potential inhibition 
activity of 3 against AChE due to the presence of three hydrogen bonds with the PAS and 
oxyanion site of 1EVE. Also, different critical hydrophobic interactions were observed 
with the CAS amino acids and HIS440, a crucial residue of the catalytic triad. Taken 
together, these preliminary findings present a starting point for development of 
multifunctional agents for the treatment of AD in future. 
 
5. Supplementary data: 
CCDC 1973469 contains the crystallographic data for compound 3. These data can be 
obtained free of charge via www.ccdc.cam.ac.uk/data_ request/cif or from the Cambridge 
         
Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (þ44) 
1223 336 033; or e-mail: deposit@ccdc.cam.ac.u.k. 
6. Acknowledgment: The authors are grateful for the financial support from Taibah 
University and the technical assistance from UTM (4F830).  M. A. Said is thankful to 
Alexander von Humboldt Stiftung, Germany, for the opportunities provided.  
 
Credit Author Statement  
Author Contributions: 
Conceptualization, N.B, A.A.A. S.Y.A. and G. A. 
Methodology and Docking, G.A. 
All authors, Writing-Review & Editing 
 D.L. and M.A.S; X-ray work 
M.A.; HSA work. 
 
CONFLICT OF INTEREST 
NO CONFLICT OF INTEREST 
 
7. References  
[1] S.L. Gaonkar, U.N. Vignesh, Synthesis and pharmacological properties of chalcones: a 
review, Res. Chem. Intermed. 43 (2017) 6043–6077. doi:10.1007/s11164-017-2977-5. 
[2] P. Singh, A. Anand, V. Kumar, Recent developments in biological activities of chalcones: 
A mini review, Eur. J. Med. Chem. 85 (2014) 758–777. 
doi:10.1016/j.ejmech.2014.08.033. 
[3] Z. Ates-Alagoz, T. Coban, E. Buyukbingol, Synthesis and Antioxidant Activity of New 
Tetrahydro-Naphthalene-Indole Derivatives as Retinoid and Melatonin Analogs, Arch. 
Pharm. (Weinheim). 339 (2006) 193–200. doi:10.1002/ardp.200500177. 
[4] S. Banerjee, E.B. Veale, C.M. Phelan, S.A. Murphy, G.M. Tocci, L.J. Gillespie, D.O. 
         
Frimannsson, J.M. Kelly, T. Gunnlaugsson, Recent advances in the development of 1,8-
naphthalimide based DNA targeting binders, anticancer and fluorescent cellular imaging 
agents, Chem. Soc. Rev. 42 (2013) 1601–1618. doi:10.1039/c2cs35467e. 
[5] K. Venkatesan, V.S. V. Satyanarayana, A. Sivakumar, Ultrasonic Assisted Synthesis of 
Naphthalene Substituted Schiff Base Derivatives and Their Antioxidant Activity Studies, 
J. Chinese Chem. Soc. 58 (2011) 583–589. doi:10.1002/jccs.201190091. 
[6] A. Rauf, H. Subhan, R. Abbasi, B. Adhikari, A.H. Shah, U.A. Rana, Q. Abbas, I.Z. 
Qureshi, H. Hussain, K. Mazhar, A. Badshah, H.B. Kraatz, A. Shah, Biological activity, 
pH dependent redox behavior and UV-Vis spectroscopic studies of naphthalene 
derivatives, J. Photochem. Photobiol. B Biol. 140 (2014) 173–181. 
doi:10.1016/j.jphotobiol.2014.07.010. 
[7] J.P. Jasinski, R.J. Butcher, A.N. Mayekar, H.S. Yathirajan, B. Narayana, Structures of 
three chalcones derived from 6-methoxy-2-naphthaldehyde, J. Chem. Crystallogr. 39 
(2009) 157–162. doi:10.1007/s10870-008-9446-3. 
[8] K. Thanigaimani, S. Arshad, N.C. Khalib, I.A. Razak, C. Arunagiri, A. Subashini, S.F. 
Sulaiman, N.S. Hashim, K.L. Ooi, A new chalcone structure of (E)-1-(4-Bromophenyl)-3-
(napthalen-2-yl)prop-2-en-1-one: Synthesis, structural characterizations, quantum 
chemical investigations and biological evaluations, Spectrochim. Acta - Part A Mol. 
Biomol. Spectrosc. 149 (2015) 90–102. doi:10.1016/j.saa.2015.04.028. 
[9] World Health Organisation, Dementia Fact Sheet No.362, World Heal. Organ. Geneva, 
Switzerland,. 2013 (2015). 
[10] M. Weinstock, Selectivity of Cholinesterase Inhibition, CNS Drugs. 12 (1999) 307–323. 
doi:10.2165/00023210-199912040-00005. 
[11] J.K. Dhanjal, S. Sharma, A. Grover, A. Das, Use of ligand-based pharmacophore 
modeling and docking approach to find novel acetylcholinesterase inhibitors for treating 
Alzheimer’s, Biomed. Pharmacother. 71 (2015) 146–152. 
doi:10.1016/j.biopha.2015.02.010. 
[12] L. Wang, Y. Wang, Y. Tian, J. Shang, X. Sun, H. Chen, H. Wang, W. Tan, Design, 
synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine 
hybrids as cholinesterase inhibitors, Bioorganic Med. Chem. 25 (2017) 360–371. 
doi:10.1016/j.bmc.2016.11.002. 
[13] X. Zhang, Q. Song, Z. Cao, Y. Li, C. Tian, Z. Yang, H. Zhang, Y. Deng, Design, synthesis 
and evaluation of chalcone Mannich base derivatives as multifunctional agents for the 
potential treatment of Alzheimer’s disease, Bioorg. Chem. 87 (2019) 395–408. 
doi:10.1016/j.bioorg.2019.03.043. 
[14] C. Tian, X. Qiang, Q. Song, Z. Cao, C. Ye, Y. He, Y. Deng, L. Zhang, Flurbiprofen-
chalcone hybrid Mannich base derivatives as balanced multifunctional agents against 
Alzheimer’s disease: Design, synthesis and biological evaluation, Bioorg. Chem. 94 
(2020) 103477. doi:10.1016/j.bioorg.2019.103477. 
[15] A.I. Bush, R.E. Tanzi, Therapeutics for Alzheimer’s Disease Based on the Metal 
Hypothesis, Neurotherapeutics. 5 (2008) 421–432. doi:10.1016/j.nurt.2008.05.001. 
[16] X. Wang, X. Wang, Z. Guo, Metal-involved theranostics: An emerging strategy for 
fighting Alzheimer’s disease, Coord. Chem. Rev. 362 (2018) 72–84. 
         
doi:10.1016/j.ccr.2018.03.010. 
[17] A. Rauk, The chemistry of Alzheimer’s disease, Chem. Soc. Rev. 38 (2009) 2698. 
doi:10.1039/b807980n. 
[18] K.P. Kepp, Bioinorganic chemistry of Alzheimer’s disease, Chem. Rev. 112 (2012) 5193–
5239. doi:10.1021/cr300009x. 
[19] J.H. Viles, Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, 
zinc and iron in Alzheimer’s, Parkinson’s and prion diseases, Coord. Chem. Rev. 256 
(2012) 2271–2284. doi:10.1016/j.ccr.2012.05.003. 
[20] M. Kawahara, M. Kato-Negishi, Link between Aluminum and the Pathogenesis of 
Alzheimer’s Disease: The Integration of the Aluminum and Amyloid Cascade 
Hypotheses., Int. J. Alzheimers. Dis. 2011 (2011) 276393. doi:10.4061/2011/276393. 
[21] C.X. Xie, M.P. Mattson, M.A. Lovell, R.A. Yokel, Intraneuronal aluminum potentiates 
iron-induced oxidative stress in cultured rat hippocampal neurons, Brain Res. 743 (1996) 
271–277. doi:10.1016/S0006-8993(96)01055-4. 
[22] G. Aljohani, D. Lentz, M.A. Said, S.Y. Alraqa, A.A. Ali, N. Basar, Crystal Structure of 2-
(prop-2-yn-1-yloxy)-1-naphthaldehyde, C14H10O2, Zeitschrift Für Krist. - New Cryst. 
Struct. 234 (2019) 977–978. doi:10.1515/ncrs-2019-0195. 
[23] G. Aljohani, M.A. Said, D. Lentz, N. Basar, A. Albar, S.Y. Alraqa, A. Al-Sheikh Ali, 
Microwave-Assisted Synthesis of Mono- and Disubstituted 4-hydroxyacetophenone 
Derivatives via Mannich Reaction: Synthesis, XRD and HS-Analysis, Molecules. 24 
(2019) 590. doi:10.3390/molecules24030590. 
[24] V. Calvino, M. Picallo, A.J. López-Peinado, R.M. Martín-Aranda, C.J. Durán-Valle, 
Ultrasound accelerated Claisen-Schmidt condensation: A green route to chalcones, Appl. 
Surf. Sci. 252 (2006) 6071–6074. doi:10.1016/j.apsusc.2005.11.006. 
[25] M.J. Climent, A. Corma, S. Iborra, J. Primo, Base catalysis for fine chemicals production: 
Claisen-schmidt condensation on zeolites and hydrotalcites for the production of 
chalcones and flavanones of pharmaceutical interest, J. Catal. 151 (1995) 60–66. 
doi:10.1006/jcat.1995.1008. 
[26] M.R. Jayapal, K. Sreenivasa Prasad, N.Y. Sreedhar, Synthesis and characterization of 2,4-
dihydroxy substituted chalcones using aldol condensation by SOCl 2 / EtOH, J. Chem. 
Pharm. Res. 2 (2010) 127–132. www.jocpr.com. 
[27] O.D. Rigaku, CrysAlis PRO Software System, Rigaku Oxford Diffr. Ltd, Yarnton, 
Oxfordshire, Engl. (2018). 
[28] G.M. Sheldrick, (a) SHELXT – Integrated space-group and crystal-structure determination. 
Acta Crystallogr. Sect. A Foundations and Advances 71, (2015) 3-8. 
doi.org/10.1107/S2053273314026370; (b) Crystal structure refinement with SHELXL, 
Acta Crystallogr. Sect. C Struct. Chem. 71 (2015) 3–8. doi:10.1107/S2053229614024218. 
[29] L.J. Farrugia, WinGX and ORTEP for Windows: An update, J. Appl. Crystallogr. 45 
(2012) 849–854. doi:10.1107/S0021889812029111. 
[30] M.J. Turner, J.J. McKinnon, S.K. Wolff, D.J. Grimwood, P.R. Spackman, D. Jayatilaka, 
M.A. Spackman, CrystalExplorer. Version 17. University of Western Australia, (2017). 
         
[31] I. Hamad, H. AbdElgawad, S. Al Jaouni, G. Zinta, H. Asard, S. Hassan, M. Hegab, N. 
Hagagy, S. Selim, Metabolic Analysis of Various Date Palm Fruit (Phoenix dactylifera L.) 
Cultivars from Saudi Arabia to Assess Their Nutritional Quality, Molecules. 20 (2015) 
13620–13641. doi:10.3390/molecules200813620. 
[32] Y.-H. Koay, A. Basiri, V. Murugaiyah, K.-L. Chan, Isocorilagin, a Cholinesterase 
Inhibitor from Phyllanthus niruri, Nat. Prod. Commun. 9 (2014) 515–517. 
doi:10.1177/1934578X1400900423. 
[33] G.M. Morris, H. Ruth, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. 
Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor 
flexibility, J. Comput. Chem. 30 (2009) 2785–2791. doi:10.1002/jcc.21256. 
[34] Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2017, San 
Diego: Dassault Systèmes, (2016). 
[35] F.H. Allen, O. Kennard, D.G. Watson, L. Brammer, A.G. Orpen, R. Taylor, Tables of 
bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic 
compounds, J. Chem. Soc. Perkin Trans. 2. 0 (1987) S1. doi:10.1039/p298700000s1. 
[36] C.F. Macrae, P.R. Edgington, P. McCabe, E. Pidcock, G.P. Shields, R. Taylor, M. Towler, 
J. Van De Streek, Mercury: Visualization and analysis of crystal structures, J. Appl. 
Crystallogr. 39 (2006) 453–457. doi:10.1107/S002188980600731X. 
[37] L.H. Abdel-Rahman, R.M. El-Khatib, L.A.E. Nassr, A.M. Abu-Dief, Synthesis, 
physicochemical studies, embryos toxicity and DNA interaction of some new Iron(II) 
Schiff base amino acid complexes, J. Mol. Struct. 1040 (2013) 9–18. 
doi:10.1016/j.molstruc.2013.02.023. 
[38] L.H. Abdel-Rahman, R.M. El-Khatib, L.A.E. Nassr, A.M. Abu-Dief, M. Ismael, A.A. 
Seleem, Metal based pharmacologically active agents: Synthesis, structural 
characterization, molecular modeling, CT-DNA binding studies and in vitro antimicrobial 
screening of iron(II) bromosalicylidene amino acid chelates, Spectrochim. Acta - Part A 
Mol. Biomol. Spectrosc. 117 (2014) 366–378. doi:10.1016/j.saa.2013.07.056. 
[39] G. Kryger, I. Silman, J.L. Sussman, Structure of acetylcholinesterase complexed with 
E2020 (Ariceptρ): Implications for the design of new anti-Alzheimer drugs, Structure. 7 
(1999) 297–307. doi:10.1016/S0969-2126(99)80040-9. 
[40] G. Johnson, S. Moore, The Peripheral Anionic Site of Acetylcholinesterase: Structure, 
Functions and Potential Role in Rational Drug Design, Curr. Pharm. Des. 12 (2005) 217–
225. doi:10.2174/138161206775193127. 
[41] N.A. Hosea, Z. Radić, I. Tsigelny, H.A. Berman, D.M. Quinn, P. Taylor, Aspartate 74 as a 
Primary Determinant in Acetylcholinesterase Governing Specificity to Cationic 
Organophosphonates, Biochemistry. 35 (1996) 10995–11004. doi:10.1021/bi9611220. 
[42] J.L. Sussman, M. Harel, F. Frolow, C. Oefner, A. Goldman, L. Toker, I. Silman, Atomic 
structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-
binding protein, Science (80-. ). 253 (1991) 872–879. doi:10.1126/science.1678899. 
 
  
         
GRAPHICAL ABSTRACT 
 
         
